Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 12/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9376417 | 0.83 | ALDH1A1 (0.48) | AOC3MAOBMAPT | |
| SCHEMBL14340874 | 0.79 | NPC1 (0.41) | AOC3NPC1RAB9ARXFP1 | |
| SCHEMBL1787725 | 0.79 | KDM4E (0.43) | HDAC1HDAC6NPC1RAB9ARXFP1 | |
| SCHEMBL1786698 | 0.77 | KMT2A (0.47) | NPC1RAB9ARXFP1 | |
| SCHEMBL6788722 | 0.77 | AOC3 (0.50) | AOC3MAOBNR3C2GFERHDAC1 | |
| SCHEMBL8934638 | 0.76 | AOC3 (0.68) | AOC3MAPT | |
| SCHEMBL3934166 | 0.75 | AOC3 (0.85) | AOC3MAOB | |
| SCHEMBL15305786 | 0.73 | KDM4E (0.46) | NPC1RAB9ARXFP1 | |
| SCHEMBL5629171 | 0.70 | KDM4E (0.46) | MAPTNPC1RAB9ARXFP1 | |
| SCHEMBL14298343 | 0.70 | L3MBTL1 (0.54) | MAPTCYP2C9NPC1RAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
| EP-0356234-B1 | New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-05-11 | — | — | EP | disclosed |
| US-5047411-A | Antiulcer Agents, H2-Receptor Antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0356234-A2 | New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | AOC3 274/4885MAOB 10/4885NR3C2 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.